FM
fazen.markets
healthcare·esfritzh

Xtant Medical Q3 Revenue Falls 27% to $24.3M, Cuts 2026 Guidance

2h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

xtant-medicalxtnt-stockmedical-devicesearnings-missstrategic-review
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Xtant's core biologics business is growing, but a 27% revenue decline, a $3.6 million net loss and a guidance withdrawal have pushed the board into a strategic review with no timetable.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Xtant Medical Holdings (NYSE American: XTNT) reported third quarter 2026 revenue of $24.3 million on 16 November 2026, down from $33.3 million a year earlier, while swinging to a net loss of $3.6 million, or $0.03 per share, from net income of $1.3 million a year ago. The company withdrew its full-year 2026 guidance and said its board has launched a strategic review.

Context — Why Xtant's Q3 Miss Matters Now

The quarter marks the second consecutive period in which results fell short of the company's own guidance, a point Chairman Stavros Vizirgianakis addressed directly. "That is unacceptable," he said, adding that the board feels the shortfall "as owners and stewards of the Company, not just as directors." The admission matters because Xtant had already guided the market twice this year, and the miss signals that the company's revenue base is still shrinking faster than its cost cuts can offset.

The year-over-year decline is largely structural rather than operational. Xtant divested its non-core Coflex/CoFix assets and international hardware business, removing $5.4 million of prior-year revenue, and lost $5.5 million of wound care licensing revenue that did not recur. Those two items alone account for $10.9 million of the $9.0 million total revenue decline, meaning underlying product sales actually improved once divestitures and licensing are stripped out.

The board's decision to launch a strategic review now reflects the gap between the company's remaining biologics franchise and its overall cost structure. The review will examine operational initiatives, capital allocation, partnerships, restructurings, financings, acquisitions, dispositions and business combinations. The board gave no timetable and warned there is no assurance the process produces any specific action.

Macro conditions for small-cap medical device issuers remain difficult. Xtant carries $22 million of total indebtedness against $7.8 million of cash, and its revolving credit facility has just $2.1 million of availability. That combination of thin liquidity and covenant-sensitive debt limits the company's room to maneuver while the review runs.

Data — What the Numbers Show

The revenue comparison is stark across every line. Total revenue fell to $24.3 million from $33.3 million, a 27% decline, though it rose 5% sequentially from $23.0 million in the second quarter of 2026. Product revenue alone was $24.3 million versus $27.8 million a year ago, while license revenue dropped to zero from $5.5 million.

Biologics was the one clear bright spot. That segment generated $19.3 million, up 13% from $17.1 million a year earlier and up 11% from $17.4 million in the prior quarter. The quarter included $2.2 million from HEMOBLAST Bellows sales, a product Xtant distributes under an exclusive U.S. agreement. Excluding HEMOBLAST and products affected by wound care reimbursement, biologics product revenue grew 8% sequentially and 6% year over year, a non-GAAP measure the company provided.

Margins compressed sharply. Gross margin fell to 56.3% from 66.1%, a 980-basis-point drop. The company attributed 670 basis points of that to the loss of high-margin wound care licensing revenue and 360 basis points to sales mix. Operating expenses declined to $16.7 million from $19.5 million, with G&A down to $5.0 million from $7.1 million and sales and marketing down slightly to $11.2 million from $11.7 million.

Adjusted EBITDA swung to a loss of $1.5 million from positive $4.5 million a year ago, a $6.0 million deterioration. On the balance sheet, cash fell to $7.8 million from $17.1 million at year-end 2025, while total debt declined to $22 million from $25.4 million.

Analysis — What It Means for Xtant and Its Sector

For Xtant specifically, the strategic review is now the dominant variable. A company with a $37.3 million equity base, $6.1 million of goodwill and a shrinking revenue line is a candidate for any number of outcomes, from a sale of the biologics franchise to a full business combination. The board's language about evaluating "a broad range of potential actions" is deliberately open-ended, and the company said it will not disclose further developments unless it approves a specific action.

The biologics momentum is the strongest counter-argument to the bear case. Two consecutive quarters of double-digit year-over-year growth in that segment, plus a sequential acceleration, suggest the core franchise is stabilizing even as reported totals fall. If the review results in a focused biologics company with a lower cost base, the current revenue trajectory could look materially different from the headline decline.

The risk is liquidity. Xtant's credit agreements carry minimum liquidity and net revenue covenants, and the company acknowledged in its forward-looking statements that it may need future amendments or waivers. With $2.1 million of revolver availability and a $3.6 million quarterly net loss, the margin for error is narrow. The company said it expects cash and availability to fund operations for at least the next 12 months based on its current plan.

Positioning around small-cap medtech names like Xtant tends to be event-driven. The absence of a conference call this quarter removes a near-term catalyst for management to answer questions, and the strategic review creates a binary setup that could attract special-situation investors while deterring generalist healthcare funds.

Outlook — What to Watch Next

The company said it will file its Quarterly Report on Form 10-Q on or about 16 November 2026, which will provide the full financial detail behind the release. That filing is the next scheduled disclosure point.

The strategic review has no timetable, and the company said it does not intend to disclose developments unless the board approves a specific action. Any announcement of a transaction, partnership or restructuring would be the key catalyst.

Biologics revenue growth is the operating metric to track. Two more quarters of double-digit growth would validate the board's claim that the core franchise is gaining momentum. A reversal would undercut the central argument for holding through the review.

Frequently Asked Questions

What does Xtant Medical's guidance withdrawal mean for investors?

Xtant said it no longer expects to achieve its previously issued full-year 2026 guidance and will not provide revised guidance while the strategic review is underway. That leaves investors without a forward revenue or earnings anchor for the first time this year. The company did say it remains committed to scaling its biologics franchise, but offered no numerical target to replace the withdrawn outlook.

Why did Xtant's gross margin fall so sharply in Q3 2026?

The company attributed the drop to 56.3% from 66.1% to two factors. The cessation of high-margin wound care licensing revenue accounted for 670 basis points of the decline, and sales mix accounted for another 360 basis points. Licensing revenue is typically near-100% margin, so its disappearance mechanically lowers the blended rate even when product gross margins are stable.

Is Xtant Medical's cash position a concern?

Xtant ended the quarter with $7.8 million of cash, down from $17.1 million at December 31, 2025, plus $2.1 million of revolver availability. Total debt was $22 million. The company said it expects current cash and availability to fund operations for at least 12 months, but its credit agreements include minimum liquidity and net revenue covenants that could require future amendments or waivers.

Bottom Line

Xtant's core biologics business is growing, but a 27% revenue decline, a $3.6 million net loss and a guidance withdrawal have pushed the board into a strategic review with no timetable.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related